移动健康干预促进结核病患者戒烟:一项整群随机临床试验
这项多中心整群随机临床试验在孟加拉国和巴基斯坦的27家结核病诊所开展,将吸烟的结核病患者按2:1随机分配至移动健康干预组(n=720)或常规护理组(n=360),随访6个月。移动健康组6个月自我报告并经生化验证的持续戒烟率为41.7%,显著高于常规护理组的15.3%(风险比3.0,95%CI 2.0-4.9);结核病治疗成功率两组无显著差异,移动健康组死亡率较低(3.5% vs 7.5%,HR 0.4,95%CI 0.2-0.9)。
要点
- 移动健康组6个月持续戒烟率41.7%,常规护理组15.3%,风险比3.0(95%CI 2.0-4.9)。
- 结核病治疗成功率移动健康组89.3% vs 常规护理组85.6%,风险比1.2(95%CI 0.9-1.6),无显著差异。
- 死亡率移动健康组3.5% vs 常规护理组7.5%,风险比0.4(95%CI 0.2-0.9)。
核心结论
- 移动健康干预能有效帮助吸烟的结核病患者实现持续戒烟,是可行且有效的干预措施。
研究设计与样本
- 多中心整群随机临床试验,于2023年9月18日至2025年1月2日开展,将孟加拉国和巴基斯坦的27家结核病诊所按2:1随机分配至移动健康组或常规护理组,随访6个月。
- 纳入标准为年龄15岁及以上、过去4周内诊断为药物敏感性肺结核、每日吸烟、愿意戒烟且能使用手机者;共评估9232例患者,随机化1080例。
- 移动健康组(n=720)在结核病治疗期间接收短信,前2个月每日发送,后4个月每月发送,鼓励戒烟;常规护理组(n=360)接收戒烟书面信息。
主要发现
- 主要结局:移动健康组720例中300例(41.7%)在6个月时达到自我报告且经一氧化碳呼气试验生化验证的持续戒烟,常规护理组360例中55例(15.3%),风险比3.0(95%CI 2.0-4.9)。
- 结核病治疗依从性(接受结核病治疗天数):移动健康组平均174.3天(标准差21.5) vs 常规护理组178.0天(标准差12.1),P=0.23。
- 结核病治疗成功率:移动健康组89.3% vs 常规护理组85.6%,风险比1.2(95%CI 0.9-1.6)。
- 结核病治疗失败(0.1% vs 0.5%)和治疗脱失(中断结核病治疗≥2个月,3.1% vs 1.9%)均不常见。
- 死亡率:移动健康组3.5% vs 常规护理组7.5%,风险比0.4(95%CI 0.2-0.9)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Smoking worsens outcomes in people with tuberculosis (TB), while quitting hastens recovery. OBJECTIVE: To assess the effectiveness of a mobile health (mHealth) intervention for achieving self-reported continuous tobacco abstinence at 6 months, supported by biochemical verification at 6 months, compared with usual care in people with TB. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, cluster randomized clinical trial conducted between September 18, 2023, and January 2, 2025, randomizing (2:1) 27 TB clinics in Bangladesh and Pakistan to mHealth or usual care groups. The follow-up was 6 months. Participants were eligible if they were 15 years or older, had been diagnosed with drug-sensitive pulmonary TB in the past 4 weeks, smoked daily, were willing to quit, and had access to mobile phones. INTERVENTION: The mHealth group (n = 720) received text messages throughout TB treatment, daily for 2 months then monthly for 4 months, encouraging tobacco cessation. The usual care group (n = 360) received written information on tobacco cessation. MAIN OUTCOMES AND MEASURES: The primary outcome was self-reported continuous abstinence at 6 months, verified biochemically using carbon monoxide breath test at 6 months. Secondary outcomes included self-reported point abstinence at 9 weeks and 6 months, TB treatment adherence (days receiving TB treatment), TB treatment success (cured + completed treatment), TB treatment failure, TB treatment default (interruption of TB treatment for ≥2 months), and death. RESULTS: Of 9232 patients assessed for eligibility, 1080 were randomized; most were male (mHealth, 96.9%; usual care, 95.8%), and 985 were retained throughout the trial (91%). For the primary outcome, 300 of 720 participants (41.7%) in the mHealth group demonstrated self-reported and biochemically verified continuous abstinence at 6 months, compared with 55 of 360 (15.3%) in the usual care group (risk ratio, 3.0 [95% CI, 2.0-4.9]). In the mHealth vs usual care groups, respectively, mean TB treatment adherence was 174.3 (SD, 21.5) days vs 178.0 (SD, 12.1) days (P = .23), and treatment success was 89.3% vs 85.6% (risk ratio, 1.2 [95% CI, 0.9-1.6]). TB treatment failure (0.1% vs 0.5%) and default (3.1% vs 1.9%) were uncommon. Mortality was lower with mHealth (3.5%) vs usual care (7.5%) (hazard ratio, 0.4 [95%CI, 0.2-0.9]). CONCLUSIONS AND RELEVANCE: An mHealth intervention was effective in achieving continuous abstinence in people with TB who smoked. mHealth is a feasible and effective intervention to help patients with TB quit smoking. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN86971818.
引用
- Zahid M, Rahman F, Danaee M, et al. An mHealth (Mobile Health) Intervention for Smoking Cessation in People With Tuberculosis: A Cluster Randomized Clinical Trial. JAMA. 2026. PMID: 41428342. doi:10.1001/jama.2025.20765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。